One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Issue Highlights page
doi : 10.1016/S0360-3016(22)03359-4
Volume 114, Issue 5, 1 December 2022, Pages A9-A11
The Future of Treating Oligometastatic Lung Cancer Is Personalized Care
Jill Feldman, MA
doi : 10.1016/j.ijrobp.2022.09.054
Volume 114, Issue 5, 1 December 2022, Pages 822-823
The Cost-Effectiveness of Consolidative Radiation Therapy in Oligometastatic Disease: High-Value Proposition or Wishful Thinking?
David J. Sher, MD, MPH,* and Ronald C. Chen, MD, MPH, FASCO, FASTRO
doi : 10.1016/j.ijrobp.2022.09.016
Volume 114, Issue 5, 1 December 2022, Pages 824-826
Sowing the Seeds: A Case of Oligometastatic Anal Cancer 12 Years After Prostate Brachytherapy
Leila T. Tchelebi, MD
doi : 10.1016/j.ijrobp.2022.08.033
Volume 114, Issue 5, 1 December 2022, Pages 827-828
Systemic Therapy, Then Locoregional Consolidation
Roman O. Kowalchuk, MDKrishan R. Jethwa, MD
doi : 10.1016/j.ijrobp.2022.08.057
Volume 114, Issue 5, 1 December 2022, Page 829
Warily Whacking the Weeds
Neil B. Newman, MD, MSJordan Kharofa, MD
doi : 10.1016/j.ijrobp.2022.08.059
Volume 114, Issue 5, 1 December 2022, Pages 829-830
Prostrate After Prostate? Recommend Attempt for Definitive Treatment of Oligometastatic Anal Cancer After Low Dose Rate Brachytherapy
Maureen L. Aliru, MD, PhDNina N. Sanford, MD
doi : 10.1016/j.ijrobp.2022.08.038
Volume 114, Issue 5, 1 December 2022, Page 830
BID It to Win It
Brianna M. Jones, MDKaryn A. Goodman, MD
doi : 10.1016/j.ijrobp.2022.09.014
Volume 114, Issue 5, 1 December 2022, Page 831
New Growth After Planted Seeds, Treat With Rays
Kathryn E. Hitchcock, MD, PhDNicolette R. Drescher, MD
doi : 10.1016/j.ijrobp.2022.09.015
Volume 114, Issue 5, 1 December 2022, Pages 831-832
Oligometastases: Learning From the Past, Building for the Future
David A. Palma, MD, PhD
doi : 10.1016/j.ijrobp.2022.03.028
Volume 114, Issue 5, 1 December 2022, Pages 833-835
Local Therapy for Oligometastatic Disease—Cart Before the Horse?
Puneeth Iyengar, MD, PhD
doi : 10.1016/j.ijrobp.2022.09.013
Volume 114, Issue 5, 1 December 2022, Pages 836-839
Flipping the Null: Lessons From Breast Cancer and Recalibrating Expectations in Oligometastases
Rohan R. Katipally, MD,* Adam C. Olson, MD,and Steven J. Chmura, MD, PhD*
doi : 10.1016/j.ijrobp.2022.09.055
Volume 114, Issue 5, 1 December 2022, Pages 840-842
Ensuring That Health Inequities and Disparities Are Not Exacerbated in the Evolving Oligometastatic Treatment Paradigm
Sara R. Alcorn, MD, MPH, PhD,* and Curtiland Deville, Jr, MD
doi : 10.1016/j.ijrobp.2022.09.047
Volume 114, Issue 5, 1 December 2022, Pages 843-845
Moving Away From Counting the Numbers: Leveraging a Sensible Clinical Trial Design for Oligometastatic Disease and Beyond
C. Jillian Tsai, MD, PhD
doi : 10.1016/j.ijrobp.2022.09.057
Volume 114, Issue 5, 1 December 2022, Pages 846-848
Validation of the Prognostic Utility of ESTRO/EORTC Oligometastatic Disease Classification: A Secondary Analysis From the Population-Based Phase II SABR-5 Trial
S. Baker, MD, PhD,*B. Mou, MD,*W. Jiang, MD,*M. Liu, MD, CM,*A.M. Bergman, PhD,D. Schellenberg, MD,*A.S. Alexander, MD,*H. Carolan, MD,*S. Atrchian, MD,*T. Berrang, MD,*A. Bang, MD,*N. Chng, PhD,Q. Matthews, PhD,S. Tyldesley, MD,*and R.A. Olson, MD, MSc*
doi : 10.1016/j.ijrobp.2022.08.026
Volume 114, Issue 5, 1 December 2022, Pages 849-855
Predictors of Early Polymetastatic Relapse After SABR for up to 5 Oligometastases: A Secondary Analysis of the Phase II SABR-5 Trial
Sarah Baker, MD, PhD,*Benjamin Mou,*Will Jiang, MD,*Mitchell Liu, MD, CM,*Alanah M. Bergman, PhD,Devin Schellenberg, MD,*Abraham S. Alexander, MD,*Hannah Carolan,*Siavash Atrchian, MD,*Tanya Berrang, MD,*Andrew Bang, MD,*Nick Chng, PhD,Quinn Matthews, PhD,Scott Tyldesley, MD,*andRobert A. Olson, MD, MSc*
doi : 10.1016/j.ijrobp.2022.06.094
Volume 114, Issue 5, 1 December 2022, Pages 856-861
Impact of Medical Operability and Total Metastatic Ablation on Outcomes After SABR for Oligometastases
Shankar Siva, PhD,*Gavin Jones, MD,Mathias Bressel, MSc,Mark Shaw, MBChB,* Sarat Chander, MBBS,*Julie Chu, MBBS,* Nikki Plumridge, MBBS,* Keelan Byrne, MBBS,* Gargi Kothari, MBBS,*Nicholas Hardcastle, PhD,Mathieu Gaudreault, PhD,Tomas Kron, PhD,Greg Wheeler, MBBS,*Michael MacManus, MD,*Gerard G. Hanna, PhD,*David L Ball, MD,*and Steven David, MBBS*
doi : 10.1016/j.ijrobp.2022.05.034
Volume 114, Issue 5, 1 December 2022, Pages 862-870
Distant Metastasis Velocity as a Novel Prognostic Score for Overall Survival After Disease Progression Following Stereotactic Body Radiation Therapy for Oligometastatic Disease
Jonas Willmann, MD, Eugenia Vlaskou Badra, MD, Selma Adilovic, Sebastian M. Christ, MD, PhD,Maiwand Ahmadsei, MD, Michael Mayinger, MD, Stephanie Tanadini-Lang, PhD,Matthias Guckenberger, MD, and Nicolaus Andratschke, MD
doi : 10.1016/j.ijrobp.2022.06.064
Volume 114, Issue 5, 1 December 2022, Pages 871-882
A Comparison of 2 Disease Burden Assessment Methods (3D Volume Versus the Number of Lesions) for Prognostication of Survival in Metastatic Melanoma: Implications for the Characterization of Oligometastatic Disease
Jina Kim, MD,* Jee Suk Chang, MD, PhD,*,Wonmo Sung, PhD,Jin Sung Kim, PhD,* Tae Hyung Kim, MD,*,Seo Hee Choi, MD,*,Kyung Hwan Kim, MD, PhD,* Heejoo Ko, BS,Hye Sun Lee, PhD,** Soyoung Jeon, PhD,**Sang Joon Shin, MD, PhD,Mitchell Liu, MD, FRCPC,and Robert Olson, BSc, MD, FRCPC, MSc
doi : 10.1016/j.ijrobp.2022.08.040
Volume 114, Issue 5, 1 December 2022, Pages 883-891
Development of a Prognostic Model for Overall Survival in Patients With Extracranial Oligometastatic Disease Treated With Stereotactic Body Radiation Therapy
Hanbo Chen, MD, MPH,* Ian Poon, MD,* Eshetu G. Atenafu, MSc,Serena Badellino, MD,Tithi Biswas, MD,Roi Dagan, MD,Darby Erler, MRT(T),* Matthew Foote, MD,Kristin J. Redmond, MD,Umberto Ricardi, MD,Arjun Sahgal, MD,* and Alexander V. Louie, MD, MSc, PhD*
doi : 10.1016/j.ijrobp.2021.12.001
Volume 114, Issue 5, 1 December 2022, Pages 892-901
Conditional Survival of Patients With Extracranial Oligometastatic Treated With Stereotactic Body Radiation Therapy: An International Consortium Study
Hanbo Chen, MD, MPH,* Serena Badellino, MD,Tithi Biswas, MD,Roi Dagan, MD,Darby Erler, MRT(T),*Matthew Foote, MD,Ian Poon, MD,* Kristin J. Redmond, MD,Umberto Ricardi, MD,Arjun Sahgal, MD,* andAlexander V. Louie, MD, MSc, PhD*
doi : 10.1016/j.ijrobp.2022.06.073
Volume 114, Issue 5, 1 December 2022, Pages 902-909
Definitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results From the Lead-in Phase of the Randomized Basket Trial EXTEND
Alexander D. Sherry, MD,* Tharakeswara K. Bathala, MD, MBBS,Suyu Liu, PhD,Bryan M. Fellman, MS,Stephen G. Chun, MD,* Nikesh Jasani, MD,B. Ashleigh Guadagnolo, MD, MPH,* Anuja Jhingran, MD,*Jay P. Reddy, MD,* Paul G. Corn, MD, PhD,Amishi Y. Shah, MD,Kelsey W. Kaiser, MS,* Amol J. Ghia, MD,*Daniel R. Gomez, MD,*and Chad Tang, MD*
doi : 10.1016/j.ijrobp.2022.05.023
Volume 114, Issue 5, 1 December 2022, Pages 910-918
Local Treatment of the Primary Tumor for Patients With Metastatic Cancer (PRIME-TX): A Meta-Analysis
Jeffrey M. Ryckman, MD, MSMP,* Toms V. Thomas, MD,Ming Wang, PhD,Xue Wu, MS,Shankar Siva, MBBS, PhD,Daniel E. Spratt, MD,Ben Slotman, MD, PhD,Sumanta Pal, MD,**Brian F. Chapin, MD,Florian Fitzal, MD,Atilla Soran, MD, MPH,Axel Bex, MD,Alexander V. Louie, MD, PhD,Eric J. Lehrer, MD,and Nicholas G. Zaorsky, MD
doi : 10.1016/j.ijrobp.2022.06.095
Volume 114, Issue 5, 1 December 2022, Pages 919-935
Finding Resonance: Using MRI to Improve the Care of Oligometastatic Disease
Lisa Singer, MD, PhD, and Jessica Scholey, PhD
doi : 10.1016/j.ijrobp.2022.06.076
Volume 114, Issue 5, 1 December 2022, Pages 936-940
Stereotactic Magnetic Resonance-Guided Adaptive Radiation Therapy (SMART) for Abdominopelvic Oligometastases
David D. Yang, MD,* Victoria S. Brennan, MBBCh, BAO,Elizabeth Huynh, PhD,Christopher L. Williams, PhD,Zhaohui Han, PhD,Nicole Ampofo, MPH,Marie E. Vastola, BS,Paavni Sangal, MPH,Lisa Singer, MD, PhD,Raymond H. Mak, MD,Jonathan E. Leeman, MD,Daniel N. Cagney, MD,and Mai Anh Huynh, MD, PhD
doi : 10.1016/j.ijrobp.2022.05.016
Volume 114, Issue 5, 1 December 2022, Pages 941-949
MRI-guided Radiotherapy (MRgRT) for Treatment of Oligometastases: Review of Clinical Applications and Challenges
Indrin J. Chetty, PhD, Anthony J. Doemer, MS, Jennifer L. Dolan, PhD, Joshua P. Kim, PhD,Justine M. Cunningham, MS, Jadranka Dragovic, MD, Aharon Feldman, MD, Eleanor M. Walker, MD,Mohamed Elshaikh, MD, Khaled Adil, MD, Benjamin Movsas, MD, and Parag J. Parikh, MD
doi : 10.1016/j.ijrobp.2022.07.027
Volume 114, Issue 5, 1 December 2022, Pages 950-967
Cost-Effectiveness of Single Versus Multifraction SABR for Pulmonary Oligometastases: The SAFRON II Trial
Richard De Abreu Lourenco, PhD,* Terence Khoo, MEc,* Anna Crothers, MEc,* Marion Haas, PhD,*Rebecca Montgomery, BBiomedSc,David Ball, MD,Mathias Bressel, MSc,and Shankar Siva, PhD
doi : 10.1016/j.ijrobp.2022.01.024
Volume 114, Issue 5, 1 December 2022, Pages 968-976
A Systematic Review of the Cost-Effectiveness of Stereotactic Radiation Therapy for Cancer Oligometastases
Vivek Verma, MD,* Nikhil Yegya-Raman, MD,Tanja Sprave, MD,Guang Han, MD, PhD,Hagop M. Kantarjian, MD,James W. Welsh, MD,* Joe Y. Chang, MD, PhD,* and Steven H. Lin, MD, PhD*
doi : 10.1016/j.ijrobp.2022.05.042
Volume 114, Issue 5, 1 December 2022, Pages 977-988
The Impact of Disease Progression on Health-Related Quality of Life Outcomes in Patients With Oligometastatic Disease at 12 Months Post Stereotactic Body Radiation Therapy
Aisling S. Barry, MD,*Andrea Bezjak, MD,*Joelle Helou, MD,*Pamela Goodwin, MD,Alex Kiss, PhD,Jolie Ringash, MD,*Rebecca Goody, MD,Pablo Munoz-Schuffenegger, MD,Patricia E. Lindsay, PhD,*Alana Pellizzari, MRT (T),* Jan Ponichtera, MD,Zhi Hui Liu, PhD,and Rebecca Wong, MD*
doi : 10.1016/j.ijrobp.2022.07.012
Volume 114, Issue 5, 1 December 2022, Pages 989-999
Patient-Reported and Clinical Outcomes From 5-Fraction SBRT for Oligometastases: A Prospective Single-Institution Study
Rebecca K.S. Wong, MB, ChB,*Zhihui Amy Liu, PhD,Aisling Barry, MD,*Patrik Rogalla, MD,Andrea Bezjak, MD,*James D. Brierley, MD,*Laura A. Dawson, MD,*Meredith Giuliani, MD,*John Kim, MD,*Jolie Ringash, MD,*Alexander Sun, MD,*Peter Chung, MD,*Andrew Hope, MD,*Andrea Shessel, MSc,* andPatricia Lindsay, PhD*
doi : 10.1016/j.ijrobp.2022.07.025
Volume 114, Issue 5, 1 December 2022, Pages 1000-1010
Planning Trade-offs for SABR in Patients With 4 to 10 Metastases: A Substudy of the SABR-COMET-10 Randomized Trial
Samaher Ashram, MD,* Houda Bahig, MD, PhD,Aisling Barry, MD,Denise Blanchette, MRT(T),Anders Celinksi, MRT(T),* Peter Chung, MBChB,Johnson Darko, PhD,David Donath, MD,Robert Doucet, PhD,Abigail Erickson, Nat.Dip (RT),* Meredith Giuliani, MBBS, MEd, PhD,Darin Gopaul, MD,Scott Hipwell, BA, CMD,*Joanna Javor, MHSc,Joda Kuk, MD,Patricia Lindsay, PhD,Barbara Millman, MRT(T), BSc,*Michael Oliver, PhD,Andrew Pearce, MD,Catherine Russell,Sashendra Senthi, MD, PhD,Toni Vu, MD,Andrew Warner, MSc,* Stewart Gaede, PhD,* and David A. Palma, MD, PhD*
doi : 10.1016/j.ijrobp.2022.05.035
Volume 114, Issue 5, 1 December 2022, Pages 1011-1015
Determining Planning Priorities for SABR for Oligometastatic Disease: A Secondary Analysis of the SABR-COMET Phase II Randomized Trial
Matthew Van Oirschot,* Alanah Bergman, PhD,Wilko F.A.R. Verbakel, PhD,Lucy Ward, BSc,Isabelle Gagne, PhD,Vicky Huang, MSc,Nick Chng, PhD,** Peter Houston, MSc,Kerry Symes, BSc,Christopher G. Thomas, PhD,Parminder Basran, PhD,David Bowes, MD,Stephen Harrow, MBChB, PhD,Robert Olson, MD, MSc,** Suresh Senan, MBBS, PhD,Andrew Warner, MSc,* David A. Palma, MD, PhD,* andStewart Gaede, PhD*
doi : 10.1016/j.ijrobp.2022.01.002
Volume 114, Issue 5, 1 December 2022, Pages 1016-1021
In Silico Trial of Computed Tomography-Guided Stereotactic Adaptive Radiation Therapy (CT-STAR) for the Treatment of Abdominal Oligometastases
Joshua P. Schiff, MD, Hayley B. Stowe, MD, Alex Price, MS, Eric Laugeman, MS, Casey Hatscher, BA,Geoffrey D. Hugo, PhD, Shahed N. Badiyan, MD, Hyun Kim, MD, Clifford G. Robinson, MD, andLauren E. Henke, MD, MSCI
doi : 10.1016/j.ijrobp.2022.06.078
Volume 114, Issue 5, 1 December 2022, Pages 1022-1031
Normal Tissue Sparing by FLASH as a Function of Single-Fraction Dose: A Quantitative Analysis
Till Tobias Bohlen, PhD,* Jean-Francois Germond, PhD,* Jean Bourhis, MD, PhD,Marie-Catherine Vozenin, PhD,Esat Mahmut Ozsahin, MD, PhD,Francois Bochud, PhD,* Claude Bailat, PhD,* and Raphael Moeckli, PhD*
doi : 10.1016/j.ijrobp.2022.05.038
Volume 114, Issue 5, 1 December 2022, Pages 1032-1044
Automated Computer-Aided Detection of Lung Nodules in Metastatic Colorectal Cancer Patients for the Identification of Pulmonary Oligometastatic Disease
Jason Joon Bock Lee, MD,*Young Joo Suh, MD, PhD,Caleb Oh, BS,* Byung Min Lee, MD,* Jin Sung Kim, PhD,*Yongjin Chang, MS,Yeong Jeong Jeon, MD, PhD,Ji Young Kim, MS,Seong Yong Park, MD, PhD,andJee Suk Chang, MD, PhD*
doi : 10.1016/j.ijrobp.2022.08.042
Volume 114, Issue 5, 1 December 2022, Pages 1045-1052
PSMA PET- and mpMRI-directed Prostate Cancer Salvage
Wei Liu, MDGlenn Bauman, MD
doi : 10.1016/j.ijrobp.2022.07.006
Volume 114, Issue 5, 1 December 2022, Pages 1053-1054
Erratum to: Diffusion-Weighted Magnetic Resonance Imaging-Guided Dose Painting in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy Plus Concurrent Chemoradiotherapy: A Randomized, Controlled Clinical Trial
Shengnan Fu, MM,Yanxian Li, MM,Yaqian Han, MM,Hui Wang, MD,Yanzhu Chen, MM,Ouying Yan, MM,Qian He, MM,Hongzhi Ma, MM,Lin Liu, MM,and Feng Liu, MD
doi : 10.1016/j.ijrobp.2022.07.013
Volume 114, Issue 5, 1 December 2022, Pages 1055-1056
NRG/RTOG 1112: Randomized Phase III Study of Sorafenib vs. Stereotactic Body Radiation Therapy (SBRT) Followed by Sorafenib in Hepatocellular Carcinoma (HCC) (NCT01730937)
doi : 10.1016/j.ijrobp.2022.09.002
Volume 114, Issue 5, 1 December 2022, Page 1057
Radiotherapy with Durvalumab vs. Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer and a Contraindication to Cisplatin: Phase II Results of NRG-HN004
L.K. Mell, 1,2 P. Torres-Saavedra, 3 S. Wong, 4 S. Chang, 5 J.A. Kish, 6 A.J. Minn, III7 R. Jordan, 8 T. Liu, 9 M.T. Truong, 10 E. Winquist, 11 T. Wise-Draper, 12 C.P. Rodriguez, 13 A. Musaddiq, 14 B.M. Beadle, 15 C. Henson, 16 S. Narayan, 17 S.A. Spencer, 18 J. Harris, 3 and S.S. Yom
doi : 10.1016/j.ijrobp.2022.09.003
Volume 114, Issue 5, 1 December 2022, Page 1058
Durvalumab in Combination with Chemoradiotherapy (CRT) in Locally Advanced Cervical Cancer (LACC): Radiotherapy (RT) Delivery and Subgroup Analyses from CALLA
J. Mayadev, 1 Y. Rong, 2 T. Toita, 3 R. Tarnawski, 4 U.M. Mahantshetty, 5 F. Rey, 6 A.T. Nunes, 7 A. Lloyd,8 S. Wildsmith, 8 H. Dry, 9 and B.J. Monk
doi : 10.1016/j.ijrobp.2022.09.004
Volume 114, Issue 5, 1 December 2022, Pages 1058-1059
Prophylactic Radiation Therapy vs. Standard-of-Care for Patients with High-Risk, Asymptomatic Bone Metastases: A Multicenter, Randomized Phase II Trial
doi : 10.1016/j.ijrobp.2022.09.005
Volume 114, Issue 5, 1 December 2022, Page 1059
Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer (EXTEND): A Multicenter, Randomized Phase II Trial
Tang, 1 A.D. Sherry,2 C. Haymaker, 2 T. Bathala,2 S. Liu, 3 B. Fellman, 3 A. Aparicio, 4 A. Zurita-Saavedra, 5 S.. Chun, 6 J. Reddy,1 E. Efstathiou, 2 J. Wang, 2 P. Pilie,2 A. Reuben, 2 C. Kovitz, 2 R. Kumar, 7 B. Chapin, 8 D.R. Gomez, 9 I. Wistuba, 10 and P.G. Corn 11
doi : 10.1016/j.ijrobp.2022.09.006
Volume 114, Issue 5, 1 December 2022, Pages 1059-1060
Celiac Plexus Radio-Surgery for Pain Management in Advanced Cancer: An International Phase II Trial
Lawrence, 1 M. Miszczyk, 2 L.A. Dawson,3 A.S. Barry, 4 D.A. Diaz Pardo, 5 A. Aguiar, 6 D. Limon,7 R.M. Pfeffer, 8 M. Buckstein, 9 H. Gnessin, 1 R. Fluss, 10 T. Meron, 11 A.P. Dicker, 12 C. Zimmermann, 13 D. Hausner, 14 O. Morag, 11 T. Golan,15 L. Freedman, 10 M. ben-Ayun, 16 and Z. Symon
doi : 10.1016/j.ijrobp.2022.09.007
Volume 114, Issue 5, 1 December 2022, Pages 1060-1061
Final Analysis of Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression Trial - A Randomized Study of Stereotactic Body Radiotherapy for Oligoprogressive Metastatic Lung and Breast Cancers
C.J. Tsai,1 J.T. Yang, 1 D.M. Guttmann, 1 N. Shaverdian, 1 J. Eng,2 R. Yeh, 3 J. Girshman, 3 J. Das, 3 D. Gelblum, 1 A.J. Xu, 1 A. Namakydoust, 2 A. Iqbal,2 J.M. Mann, 1 I. Preeshagul, 2 C. Hajj,1 E.F. Gillespie, 1 S. Modi, 2 C. Dang,2 P. Drullinsky, 2 W. Zhi, 2 Q. LaPlant, 1 A. Rimner, 1 J.Y. Shin, 1 A.J. Wu, 1 K. Ng, 2 A. Gucalp, 2 A.J. Khan, 1 R. Sanford, 2 J. Bromberg, 2 A.D. Seidman, 2 T.A. Traina, 2 D.R. Gomez, 1 J. Flynn, 4 Z. Zhang, 4 J.A. Patel, 5 M. Berger, 5 J.S. Reis-Filho, 5 N.Y. Lee,1 N. Riaz, 1 M.E. Robson, 2 C.M. Rudin, 2 and S.N. Powell
doi : 10.1016/j.ijrobp.2022.09.008
Volume 114, Issue 5, 1 December 2022, Page 1061
LUSTRE: A Phase III Randomized Trial of Stereotactic Body Radiotherapy (SBRT) vs. Conventionally Hypofractionated Radiotherapy (CRT) for Medically Inoperable Stage I Non-Small Cell Lung Cancer (NSCLC)
A. Swaminath, 1 S. Parpia, 2 M. Wierzbicki, 1 V. Kundapur, 3 S.L. Faria, 4 G. Okawara, 5 T. Tsakiridis, 2 N. Ahmed, 6 A. Bujold, 7 K.J. Hirmiz, 8 T.E. Owen,9 N. Leong, Jr10 K. Ramchandar, 11 E.J. Filion,12 H. Lau, 13 A.V. Louie, 14 K. Quan, 15 M. Levine, 16 J. Wright, 1 and T.J. Whelan 16
doi : 10.1016/j.ijrobp.2022.09.009
Volume 114, Issue 5, 1 December 2022, Pages 1061-1062
Stereotactic MR-Guided On-Table Adaptive Radiation Therapy (SMART) for Patients with Borderline or Locally Advanced Pancreatic Cancer: Primary Endpoint Outcomes of a Prospective Phase II Multi-Center International Trial
P.J. Parikh,1 P. Lee, 2 D. Low, 3 J. Kim, 1 K.E. Mittauer, 4 M.F. Bassetti, 5 C. Glide-Hurst, 5 A. Raldow,6 Y. Yang, 6 L. Portelance, 7 B. Zaki, 8 H. Kim, 9 J.D. Mancias, 10 J. Ng, 11 R.M. Pfeffer, 12 A. Mueller, 13 P. Kelly, 14 L. Boldrini, 15 M. Fuss, Jr 16 and M.D. Chuong 17
doi : 10.1016/j.ijrobp.2022.09.010
Volume 114, Issue 5, 1 December 2022, Pages 1062-1063
GETUG-AFU 22 Phase II Randomized Trial Evaluating Outcomes of Post-Operative Immediate Salvage Radiation Therapy with or without ADT for Patients with Persistently Elevated PSA Level
I. Latorzeff, 1 S. Guerif, 2 F. Castan, 3 E. Meyer, 4 S. Supiot, 5 E. Lagneau,6 E. Deniaud-Alexandre, 7 P. Ronchin, 8 A. Benyoucef, 9 L. Cartier, 10,11 H. Hamidou, 12 G. Crehange, 13 P. Pommier, 14 N. Magne, 15 M. Zibouche, 16 E. Gross, 17 G. Ploussard, 18 L. Salomon, 19 and P. Sargos20
doi : 10.1016/j.ijrobp.2022.09.011
Volume 114, Issue 5, 1 December 2022, Page 1063
Patterns of Failure after Stereotactic Radiosurgery vs. Whole Brain Radiotherapy for Resected Brain Metastases: Central Imaging Review of the N107C/CEC.3 (Alliance) Phase III Clinical Trial
W. Breen, 1 K.E. Dooley, 2 E. Twohy, 2 P.D. Brown, 1 K. Ballman, 3 J.H. Cerhan, 4 J.J. Urbanic, 5 A.C. Whitton, 6 J. Greenspoon, 6 I.F. Parney, 7 N.N. Laack, II1 J.P. Bahary, 8 F. Barker, 9 D. Khuntia, 10 C. Giannini, 11 E. Galanis, 4 D. Roberge, 12 and J.B. Ashman13
doi : 10.1016/j.ijrobp.2022.09.012
Volume 114, Issue 5, 1 December 2022, Pages 1063-1064
Robustness of a multi-isocenter VMAT Total Body Irradiation (TBI) dose distribution against daily patient setup errors
E. Seravalli, 1 M. Willemsen-Bosman, 1 G.O.R. Janssens, 1 and B.A.W. Hoeben
doi : 10.1016/j.ijrobp.2022.09.019
Volume 114, Issue 5, 1 December 2022, Page 1066
Radiotherapy Quality Assurance in SIOP Ependymoma II – Experiences from Germany, Austria and Switzerland
J. Merta, 1 K. Jakob, 1 Y.L. Lin, 2 P.H. Kramer, 1 S. Plaude, 1 C. Behrends, 1 M. Stickan-Verf€urth, 2 D. Geismar, 2 M. Mynarek, 3 S. Dietzsch, 4 R.D. Kortmann, 4 M. Benesch, 5 N. Gerber, 6 S. Rutkowski, 3 and B. Timmermann
doi : 10.1016/j.ijrobp.2022.09.020
Volume 114, Issue 5, 1 December 2022, Page 1066
Low-dose proton radiotherapy for pediatric choroidal hemangioma
M. Ioakeim-Ioannidou, 1 F. Jovany, 2 L. Kevin, 1 C. Yen-Lin, 1 K. Ivana, 3 G. Evangelos, 3 M. Shizuo, 3 and M. Shannon 1
doi : 10.1016/j.ijrobp.2022.09.021
Volume 114, Issue 5, 1 December 2022, Pages 1066-1067
Comprehensive Radiotherapy For Pediatric Ewing Sarcoma: Outcomes of a Prospective Proton Study
J. Bronk, 1 M. Zhang, 2 M.F. Mcaleer, 1 S. Mcgovern, 1 Y. Lassen-Ramshad, 3 A. Safwat, 3 N. Daw, 1 N. Rainusso, 4 A. Mahajan, 5 D. Grosshans, 1 and A. Paulino 1
doi : 10.1016/j.ijrobp.2022.09.022
Volume 114, Issue 5, 1 December 2022, Page 1067
Feasibility of proton beam therapy as a rescue therapy in heavily pre-treated retinoblastoma eyes
E. Biewald, 1 T. Kiefer, 1 G. Dirk, 2 S. Sabrina, 1 G. Sophia, 3 W. J€org,2 T. Beate, 2 K. Petra, 4 S. Stefan, 4 T. Saskia, 5 and B. Nikolaos 1
doi : 10.1016/j.ijrobp.2022.09.023
Volume 114, Issue 5, 1 December 2022, Page 1067
Pediatric Radiotherapy Utilization rate (PUR) in a large pediatric oncology center in Low-/Middle-Income country (LIMC): Report on 14473 patients
M. Zaghloul
doi : 10.1016/j.ijrobp.2022.09.024
Volume 114, Issue 5, 1 December 2022, Pages 1067-1068
Radiotherapy within the interdisciplinary treatment strategy for pediatric extracranial germ cell tumors
L. Schmidt, 1 M. Stickan-Verf€urth, 1 S. Schuckel, 1 H. Thomas, 1 G. Calaminus, 2 and B. Timmermann
doi : 10.1016/j.ijrobp.2022.09.025
Volume 114, Issue 5, 1 December 2022, Page 1068
Interfractional diaphragm and abdominal organ motion in 189 children during radiotherapy: a multicenter study
K.M. Meijer, 1 I.W. Van Dijk, 1 M. Frank, 1 A.D. Van Den Hoek, 1 B.V. Balgobind, 1 G.O. Janssens, 2 M. Wendling, 3 J.H. Maduro, 4 A. Bryce-Atkinson, 5 A. Loginova, 6 and A. Bel
doi : 10.1016/j.ijrobp.2022.09.026
Volume 114, Issue 5, 1 December 2022, Pages 1068-1069
Evaluation of repeated sedation in children during proton beam radiotherapy: Experiences from a large monoinstitutional cohort
. Langemeyer, 1 S. Peters, 1 S. Frisch, 1 S. Tippelt, 2 C. Blase, 3 and B. Timmermann
doi : 10.1016/j.ijrobp.2022.09.027
Volume 114, Issue 5, 1 December 2022, Page 1069
Establishment of a UK national referral service for paediatric brachytherapy
M. Gaze, 1 N. Smeulders, 2 G. Sands, 1 T. Sullivan, 1 N. Bal, 1 E. Gill,1 C. Peet,1 O. Slater, 2 H. Rees, 3 T. Nguyen, 1 P. Humphries, 1 D. Pendse, 1 C. Allen,1 S. Polhill, 1 R. Ackwerh, 1 P. Lim, 1 G. Eminowicz, 1 and P. Hoskin
doi : 10.1016/j.ijrobp.2022.09.028
Volume 114, Issue 5, 1 December 2022, Page 1069
A randomised phase II trial of radiotherapy dose escalation, facilitated by intensity-modulated arc therapy techniques, in high-risk neuroblastoma
J. Gains, 1 A. Patel, 2 H. Mandeville, 3 C. Stacey, 1 G. Smyth, 4 J. Talbot, 4 Y.C. Chang, 1 K. Wheatley, 2 and M. Gaze
doi : 10.1016/j.ijrobp.2022.09.029
Volume 114, Issue 5, 1 December 2022, Page 1069
Target and organ-at-risk (OAR) delineation for VMAT craniospinal irradiation using Raystation's Automatic Atlas Based Segmentation
C. Souici, 1 T. Courtot, 2 L. Klobowski, 1 I. Blasiak-Wal, 1 L. Welsh, 1 and H. Mandeville
doi : 10.1016/j.ijrobp.2022.09.030
Volume 114, Issue 5, 1 December 2022, Pages 1069-1070
Spatial normalisation for novel MR-image based data mining in children with brain tumours
A. Bryce-Atkinson, 1 L.J. Wilson, 2 E. Vasquez Osorio, 1 T. Russell,2 F. Pirlepesov, 2 A. Green, 1 A.M. Faught, 2 M.G. Mccabe, 1 T.E. Merchant, 2 M. Van Herk, 1 and M.C. Aznar 1
doi : 10.1016/j.ijrobp.2022.09.031
Volume 114, Issue 5, 1 December 2022, Page 1070
Brainstem toxicity after proton or photon therapy in children with localized intracranial ependymoma
C. Dalmasso, 1 C. Alapetite, 2 S. Bolle, 3 F. Tensaouti, 1 A. Lusque, 1 J. Desrousseaux, 1 L. Claude,4 J. Doyen,5 S. Supiot, 6 V. Bernier-Chastagner, 7 P. Leblond, 8 A. Ducassou, 1 P. Peran, 9 A. Sevely, 10 M. Roques, 10 and A. Laprie
doi : 10.1016/j.ijrobp.2022.09.032
Volume 114, Issue 5, 1 December 2022, Pages 1070-1071
Does hippocampal atrophy correlate with patient-reported adaptive function one year following radiotherapy? Results from a prospective trial
M. Hall,1 C. Rojas, 1 K. Von Werne, 1 R. Hamilton, 1 B. Currier, 1 R. Kotecha, 1 A. Mohler, 1 N. Kalman, 1 T. Niazi,
doi : 10.1016/j.ijrobp.2022.09.033
Volume 114, Issue 5, 1 December 2022, Page 1071
Patterns of Treatment Gaps and Opportunities for Advancement of Pediatric Radiation Therapy Services in Tertiary Care University Hospital in Pakistan - A Retrospective Audit
Y. Ahmed, 1 A.N. Abbasi, 1 N. Ali, 1 A. Hafiz,1 S. Abrar, 1 R. Tehseen, 1 M. Tariq, 1 and B.M. Qureshi 1
doi : 10.1016/j.ijrobp.2022.09.034
Volume 114, Issue 5, 1 December 2022, Page 1071
The need for consensus on delineation and dose constraints of dento-facial structures in paediatric radiotherapy: results of a SIOPe survey
A. Davey, 1 S. Pan,2 A. Bryce-Atkinson, 1 H. Mandeville, 3 G.O. Janssens, 4 S.M. Kelly,5 M. Hol, 6 V. Tang, 7 and M. Aznar 1
doi : 10.1016/j.ijrobp.2022.09.035
Volume 114, Issue 5, 1 December 2022, Pages 1071-1072
Effect of live video viewing on parents’ satisfaction and anxiety about radiotherapy introduction during radiotherapy for pediatric cancer
H. Fuji, 1 T. Fujibuchi, 1 H. Tanaka, 1 C. Hiramatsu, 1 Y. Ogawa, 2 C. Noda, 2 M. Hayakawa, 2 and K. Tanaka 2
doi : 10.1016/j.ijrobp.2022.09.036
Volume 114, Issue 5, 1 December 2022, Page 1072
Exploration of dose-toxicity for ophthalmological adverse events in pediatric head and neck rhabdomyosarcoma survivors
M. Morfouace, 1 M.L.F. Hol, 2 R.A. Schoot, 1 N. Arruti, 3 J. Wiersma, 4 H. Mandeville, 5 R. Davila-Fajardo,6 B. Pieters, 4 P. Saeed, 7 A. Bel,4 and D.J. Indelicato
doi : 10.1016/j.ijrobp.2022.09.037
Volume 114, Issue 5, 1 December 2022, Page 1072
Risk of infections following spleen irradiation–FCCSS study
C. Demoor-Goldschmidt, 1 G.M.Q. Vu-Bezin, 2 R. Allodji, 2 B. Fresneau, 3 N. Haddy, 2 F. Doz, 4 I. Diallo, 5 and F. De Vathaire
doi : 10.1016/j.ijrobp.2022.09.038
Volume 114, Issue 5, 1 December 2022, Pages 1072-1073
The Vertebrae as OARs in Paediatric Radiotherapy Clinical Trials: Initial QUARTET experience
A. Turcas, 1 S. Kelly, 2 B. Tom, 3 and H. Mandeville
doi : 10.1016/j.ijrobp.2022.09.039
Volume 114, Issue 5, 1 December 2022, Page 1073
Enhancing Childhood Cancer Care In African Low-Middle Income Countries: A Tunisian Pilot Experience
Z. Naimi, 1 M. Bohli,1 M. Ben Rejeb, 1 R. Ben Amor, 1 L. Ghorbel, 2 S. Yahyaoui, 3 N. Bouzid, 4 S. Zarraa, 3 N. Chaari, 5 A. Hamdoun, 1 J. Yahyaoui, 1 S. Meftah, 5 and L. Kochbati
doi : 10.1016/j.ijrobp.2022.09.040
Volume 114, Issue 5, 1 December 2022, Page 1073
Radiotherapy quality assurance outcome and its correlation with survival in the SIOPEN High-Risk Neuroblastoma trial (HR-NBL1/SIOPEN). A report from the radiotherapy committee
S.M. Kelly, 1 U. P€otschger, 2 H.B. Arnardottir, 3 T. Boterberg, 4 K. Dieckmann, 5 M. Beck Popovic, 6 R. Ladenstein, 3 and M.N. Gaze 7
doi : 10.1016/j.ijrobp.2022.09.041
Volume 114, Issue 5, 1 December 2022, Page 1074
Neurocognitive outcomes in pediatric brain tumor survivors treated with proton radiotherapy: a study from the Pediatric Proton/Photon Consortium Registry (PPCR)
M.P. Lawell, 1 A.C. Paulino, 2 D.J. Indelicato, 3 C. Hill-Kayser, 4 S. Perkins, 5 J. Perentesis, 6 B. Bajaj, 1 and T.I. Yock
doi : 10.1016/j.ijrobp.2022.09.042
Volume 114, Issue 5, 1 December 2022, Page 1074
Hypofractionated stereotactic body radiation therapy (SBRT) in pediatric patients: results of a national prospective multicenter study
L. Claude, 1 S. Bolle, 2 M. Morelle, 3 A. Huchet, 4 C. Vigneron, 5 A. Escande, 6 S. Chapet, 7 J. Leseur, 8 V. Bernier, 9 C. Carrie, 1 A. Barry, 10 S. Vizoso, 10E. Blanc, 10 A. Laprie, 11 and S. Supiot 12
doi : 10.1016/j.ijrobp.2022.09.043
Volume 114, Issue 5, 1 December 2022, Pages 1074-1075
Long-Term Morbidity of Children Receiving Hematopoietic Stem Cell Transplant with Total Body Irradiation Conditioning for Hematologic Malignancies
A.F. Khan, 1 Y. Xu, 1 M. Fidler-Benaoudia, 2 R. Diaz, 2 and N. Logie 1
doi : 10.1016/j.ijrobp.2022.09.044
Volume 114, Issue 5, 1 December 2022, Page 1075
Long-term impact of Irradiation of Brain Structures involved in Memory: The IMPALA prospective study
E. Baudou, 1 L. Pollidoro, 1 N. Courbieres, 1 F. Tensaouti, 2 P. Peran, 1 G. Arribarat, 1 J. Tallet, 3 J. Danna,4 J. Pariente, 1 Y. Chaix, 1 and A. Laprie 2
doi : 10.1016/j.ijrobp.2022.09.045
Volume 114, Issue 5, 1 December 2022, Page 1075
